Currently viewing the tag: "biosimilar"

On September 3, Swiss-based pharmaceutical giant Novartis launched the first American “biosimilar”—a copycat version of a complex biologic drug.  Novartis is offering it’s product Zarxio at a wholesale price that is 15% less than the wholesale price of the product it mimics: […]

Continue Reading